AbobotulinumtoxinA for the Treatment of Moderate-to-Severe Glabellar Lines: A Randomized, Dose-Escalating, Double-Blind Study

September 2021 | Volume 20 | Issue 9 | Original Article | 980 | Copyright © September 2021


Published online August 16, 2021

John Joseph MD,a Amir Moradi MD MBA,b Z. Paul Lorenc MD FACS,c Kyle Coleman MD,d Glynis Ablon MD FAAD,e Joely Kaufman-Janette MD,f Sue Ellen Cox MD,g Andrew Campbell MD,h Steven Dayan MD,i Anna-Karin Berg PhD,j Girish Munavalli MD MHS FACMSk

aClinical Testing of Beverly Hills, Encino, CA
bMoradi M.D., Vista, CA
cLorenc Aesthetic Plastic Surgery Center, New York, NY
dEtre Cosmetic Dermatology and Laser Center, New Orleans, LA
eAblon Skin Institute and Research Center, Manhattan Beach, CA
fSkin Research Institute, LLC, Coral Gables, FL
gAesthetic Solutions, PA, Chapel Hill, NC
hQuintessa Aesthetic Center – Ethiq2 Research, LLC, Mequon, WI
iDeNova Research, Chicago, IL
jGalderma, Uppsala, Sweden
kDermatology, Laser & Vein Specialists of the Carolinas, PLLC, Charlotte, NC




responder rates with ABO 50, 75, 100, and 125 U were 68.8%, 73.8%, 77.5% and 82.7%, versus 12.8% with placebo (P<0.001). Week 4 respective responder rates with ABO 50, 75, 100 U were all 97.5%, and 100% with 125 U, versus 12.8% with placebo (P<0.001). Week 24 responder rates with ABO 50, 75, 100, and 125 U were 52.5%, 65.0%, 57.5%, and 69.1%, respectively, versus 5.1% with placebo (P<0.001). Respective week 36 responder rates with ABO 50, 75, 100, and 125 U were 17.5%, 26.3%, 35.0%, and 30.9%, versus 0 responders with placebo (P<0.001). Figure 4 shows photographic results at baseline, week 4, and week 36, assessed using the ILA scale.

Median time to onset of ABO treatment effect was 2 days, regardless of dose. Onset of ABO treatment effect was reported at day 1 for 25.6% (50 U), 35.4% (75 U), 30.0% (100 U) and 41.3% (125 U), versus 8.0% with placebo.

The median time (weeks) to loss of 0 (none) or 1 (mild) score (ILA and SSA scales concurrently) with ABO 50, 75, 100 and, 125 U was 20.7, 24.0, 23.3 and 27.4, respectively, versus 17.8 with placebo. For the same subjects, the median time (weeks) for the glabellar line severity score to return to baseline/worse with ABO 50, 75, 100 and 125 U was 32.3, 34.3, 36.0, and 36.6, respectively, versus 23.7 with placebo (Figure 5). For those achieving a score of 0 (none) or 1 (mild) on the ILA scale, median time (weeks) to return to baseline score with ABO 50, 75, 100 and 125 U was 27.4, 30.3, 31.9, and 35.9, versus 13.7 with placebo. For those achieving a score of 0 (none) or 1 (mild) on the SSA scale, respective median time (weeks) to return to baseline severity score with ABO 50, 75, 100, and 125 U was 28.1, 31.9, 31.6, and 35.9, versus 16.0 with placebo.

Subject satisfaction questionnaires reported natural-looking results in each ABO group at week 4 (>97%), week 24 (>95%), and week 36 (>89%). Most were satisfied/very satisfied with their appearance at week 4 (>94%), week 24 (>83%), and week 36 (>67%), regardless of ABO dose. ABO-treated subjects were satisfied/very satisfied with aesthetic outcomes in the treatment area at week 4 (>98%), week 24 (>81%), and week 26 (>67%).
Close Menu